209 related articles for article (PubMed ID: 28397426)
21. Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice.
Caudrillier A; Mallavia B; Rouse L; Marschner S; Looney MR
PLoS One; 2015; 10(7):e0133022. PubMed ID: 26176623
[TBL] [Abstract][Full Text] [Related]
22. Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood.
Chang H; Voralia M; Bali M; Sher GD; Branch DR
Br J Haematol; 2000 Oct; 111(1):146-56. PubMed ID: 11091195
[TBL] [Abstract][Full Text] [Related]
23. Mirasol Pathogen Reduction Technology treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components.
Silliman CC; Khan SY; Ball JB; Kelher MR; Marschner S
Vox Sang; 2010 May; 98(4):525-30. PubMed ID: 19951305
[TBL] [Abstract][Full Text] [Related]
24. Is pathogen reduction an acceptable alternative to irradiation for risk mitigation of transfusion-associated graft versus host disease?
Li M; Irsch J; Corash L; Benjamin RJ
Transfus Apher Sci; 2022 Apr; 61(2):103404. PubMed ID: 35288055
[TBL] [Abstract][Full Text] [Related]
25. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products.
Pohler P; Müller M; Winkler C; Schaudien D; Sewald K; Müller TH; Seltsam A
Transfusion; 2015 Feb; 55(2):337-47. PubMed ID: 25134439
[TBL] [Abstract][Full Text] [Related]
26. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
[TBL] [Abstract][Full Text] [Related]
27. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
28. Functional inactivation of white blood cells by Mirasol treatment.
Fast LD; Dileone G; Li J; Goodrich R
Transfusion; 2006 Apr; 46(4):642-8. PubMed ID: 16584442
[TBL] [Abstract][Full Text] [Related]
29. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
Reid S; Johnson L; Woodland N; Marks DC
Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
[TBL] [Abstract][Full Text] [Related]
30. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma radiation, and photochemical treatment.
Fiebig E; Hirschkorn DF; Maino VC; Grass JA; Lin L; Busch MP
Transfusion; 2000 Jul; 40(7):761-70. PubMed ID: 10924602
[TBL] [Abstract][Full Text] [Related]
31. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.
van der Meer PF; Couture C; Hervig T; Kruit G; Devine DV; de Korte D; Kerkhoffs JL
Vox Sang; 2017 Jan; 112(1):9-17. PubMed ID: 28001293
[TBL] [Abstract][Full Text] [Related]
32. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
[TBL] [Abstract][Full Text] [Related]
33. Comparison of transfusion-outcome in patients with massive bleeding receiving pathogen-reduced platelets prepared with two different technologies.
Arcas Otero C; Pereira Saavedra A; Castrillo Fernández A; Vilariño López MD
Transfus Apher Sci; 2022 Jun; 61(3):103359. PubMed ID: 35074272
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML
Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109
[TBL] [Abstract][Full Text] [Related]
35. Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat-derived platelet concentrates.
Loh YS; Johnson L; Kwok M; Marks DC
Transfusion; 2014 Mar; 54(3):577-84. PubMed ID: 23829895
[TBL] [Abstract][Full Text] [Related]
36. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.
Abonnenc M; Crettaz D; Sonego G; Escolar G; Tissot JD; Prudent M
Transfus Clin Biol; 2019 Nov; 26(4):209-216. PubMed ID: 31563447
[TBL] [Abstract][Full Text] [Related]
37.
Hosseini E; Kianinodeh F; Ghasemzadeh M
Platelets; 2022 Jul; 33(5):666-678. PubMed ID: 34697994
[TBL] [Abstract][Full Text] [Related]
38. Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions.
Ambruso DR; Thurman G; Tran K; Marschner S; Gathof B; Janetzko K; Goodrich RP
Transfusion; 2011 Jun; 51(6):1220-7. PubMed ID: 21155831
[TBL] [Abstract][Full Text] [Related]
39. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model.
Chi X; Zhi L; Vostal JG
Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563
[TBL] [Abstract][Full Text] [Related]
40. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
